



Company Overview

March 2026



Disclaimer




This presentation and the accompanying oral presentation (this "presentation") have been prepared by Kestra Medical Technologies, Ltd. (together with its subsidiaries and affiliates, the "Company") and are made solely for informational purposes only and not for any other purpose.

Certain statements in this presentation are forward-looking statements. These statements relate to future events or the future performance of the Company, as well as its business strategy and plans and objectives for future operations or its industry and are subject to a number of known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by words such as "anticipate," "believe," "continue," "contemplate," "estimate," "expect," "goal," "intend," "may," "will," "could," "predict," "potential," "might," "objective," "ongoing," "plan," "potential," "project," "seek," "shall," "should," "target," "would" and similar expressions or terminology or the negative of these words and similar expressions. All statements other than statements of historical fact could be deemed forward-looking, including any expectations regarding the Company's commercial and/or research and development initiatives; any projections of financial information, market opportunities or profitability; any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements largely on its current expectations, assumptions, estimates and projections.

While the Company believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risk and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, the Company assumes no obligation and does not intend to update any of these forward-looking statements after the date of this presentation or to conform these statements to actual results or revised expectations. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on its forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. This data involves a number of assumptions, estimates, forecasts, projections, market research or similar methodologies and is inherently subject to limitations and actual event or circumstances may differ materially from events and circumstances that are assumed in this information. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These factors could cause results to differ materially from those expressed in these estimates, publications and reports by third parties of the Company.

Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names referred to in this presentation appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, the Company's rights or the right of the applicable licensor to these trademarks and tradenames. By attending or receiving this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the Company's market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of its business. The results of studies referenced in this presentation rely on various algorithms and apply only to the algorithm version that was in use at the time of the analysis and do not reflect any subsequent algorithm updates. In addition, some were conducted or supported by the Company.

The Kestra Opportunity



Underserved Market with Urgent Clinical Need



Differentiated, Clinically-Proven ASSURE System



\$10B U.S. Opportunity with Clear \$1B Go-Get Today



Scalable Business with Attractive Financial Profile



Proven Leadership Team

Innovating At-Home Cardiac Care

Lifesaving technology for patients at elevated risk of Sudden Cardiac Arrest (SCA)

Who We Are

Kestra is a **wearable** medical device and **digital** healthcare company focused on **transforming** patient outcomes using **monitoring** and **therapeutic technologies** that are intuitive, intelligent, and connected.

Cardiac Recovery System[®]

The Cardiac Recovery System, anchored by the ASSURE[®] WCD, bridges a critical gap in sudden cardiac death protection—pairing proven therapy with actionable insights to guide recovery.



Cardiac Recovery System (CRS)

Seasoned MedTech Leadership Team



Recent additions strengthen commercial and public company leadership capabilities



Brian Webster
President & CEO
33 years



Vaseem Mahboob
CFO
23 years



Traci Umberger
CAO & General Counsel
34 years



Al Ford
CCO
20 years



Timothy Moran
Chief Business Officer
25 years



Phil Foshee
SVP R&D
34 years



Debra Schotz
SVP Marketing
33 years



Jeff Laub
SVP Operations
26 years



Gordon Teddy
CIO
31 years



Christine Schlenker
VP Revenue Cycle
27 years



Beverly Magrane
VP QA/RA
42 years



Neil Bhalodkar
VP Investor Relations
20 years

*Years listed reference professional experience within the MedTech industry

Key Milestones Fueling Commercial Progress

A track record of key achievements and execution



2014

Formed by Experienced Executives from Leading External Defibrillator Company



2020

Completed ACE-CONVERT Clinical Trial

2022

100M+
Covered Lives
Full Commercial Launch in August



2025

Initial Public Offering

33,000+
Patients Protected¹
290M+
Covered Lives¹



Today

Completed Post-Approval Study
Positive Late-Breaking Results Presented at AHA 2025



2019

Completed ACE-DETECT Pivotal Study



2021

FDA Premarket Approval (PMA) Achieved
First Patient Protected by ASSURE WCD

1. As of January 2026

SCA Continues to Be a Leading Cause of Death

Rapid defibrillation is the proven therapy to restore the fibrillating heart to normal

Sudden Cardiac Arrest (SCA)

SCA is the sudden loss of heart function, resulting in immediate loss of blood flow.

~436K

Deaths Per Year
Are Caused by SCAs¹

73%

Occur at Home
or Residence¹


50%

of SCAs Are
Unwitnessed¹

7 Min

Average Time from 911
Call to EMS Arrival¹

Chances of Survival Post Cardiac Arrest¹




1. Based on data from the American Heart Association and other third-party estimates

First 90 Days Post Diagnosis Equals Highest Risk

Sudden cardiac arrest (SCA) does not wait

Appropriate WCD shock rates during the ICD waiting period comparable to early landmark ICD trials



WCD Rates have been annualized for comparison to ICD Trials

ICDs are a Class I indication to protect patients from SCA and have a mandatory 90 day waiting period for most patients

As shown in landmark ICD and WCD trials, these patients face a significant SCA risk but are **commonly left unprotected** during the ICD waiting period

Post-MI patients without an intervention have a 40-day waiting period

Moss, Arthur J., et al. "Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction." *New England Journal of Medicine*, vol. 346, no. 12, 21 Mar. 2002, pp. 877–883

Kadish, Alan, et al. "Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy." *New England Journal of Medicine*, vol. 350, no. 21, 20 May 2004, pp. 2151–2158

Bardy, Gust H., et al. "Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure." *New England Journal of Medicine*, vol. 352, no. 3, 20 Jan. 2005, pp. 225–237.

Olgin, Jeffrey E., et al. "Wearable cardioverter–defibrillator after myocardial infarction." *New England Journal of Medicine*, vol. 379, no. 13, 27 Sept. 2018, pp. 1205–1215.

Garcia, Rodrigue, et al. "Wearable cardioverter–defibrillator in patients with a transient risk of sudden cardiac death: The WEARIT-france cohort study." *EP Europace*, vol. 23, no. 1, 30 Nov. 2020, pp. 73–81.

Kutyifa, Valentina, et al. "Use of the wearable cardioverter defibrillator in high-risk cardiac patients." *Circulation*, vol. 132, no. 17, 27 Oct. 2015, pp. 1613–1619, <https://doi.org/10.1161/circulationaha.115.015677>.


Duncker, David, et al. "Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter–defibrillator: The German nationwide SCD-protect study." *European Heart Journal*, 29 Aug. 2025

Al-Khatib, Sana M., et al. "2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death." *Circulation*, vol. 138, no. 13, 25 Sept. 2018

Unlocking a \$10B U.S. Market Opportunity



Recent high-impact clinical publications have potential to impact clinical guidelines for WCD prescription



Drivers of Broader Adoption

- Better patient experience improves adherence across this extended wear period – solves compliance issue
- Proven med-tech market expansion when second competitor comes to market
- 40,000+ patient studied and published in 2025 provide strong support for improvement of guideline recommendations

* Based on internal and third-party estimates. TAM is based on current Medicare reimbursement rates, average WCD prescription duration, and approximately 850,000 cardiac patients per year eligible for a WCD.

\$1B+ Global Sales Despite Legacy Product Challenges



Therapeutic benefits are clear but depend on patient compliance

2018 VEST Intention-to-treat Analysis¹

Did not show statistically significant reduction in arrhythmic death and as-treated analysis suggested poor WCD compliance was the primary driver

75%

of deaths in WCD arm of study occurred when patients were not wearing the WCD

2020 VEST Per-protocol Analysis¹

After censoring non-compliant patients, results showed:


62%

Reduction in arrhythmic death among compliant WCD wearers

75%

Reduction in all-cause mortality among compliant WCD wearers

Incidence of Arrhythmic Death in 2020 Per-protocol Analysis of the VEST Trial¹



1. Based on third-party study

*Although the initial intention-to-treat analysis of the WCD therapy in the VEST study published 2018 did not indicate a significantly lower rate in sudden death and total mortality when compared to GDMT alone, a subsequent as-treated analysis of the data showed a significantly lower percentage of patients died when they were wearing the WCD than when they were not. This suggested that poor patient compliance with wearing the WCD was a primary factor of the intention-to-treat results.

Cardiac Recovery System Platform



A powerful cardiac care ecosystem
establishing a halo of protection

ASSURE[®] WCD

Optimizing comfort &
patient compliance



ASSURE

Patient App

Connecting patients &
providers



ASSURE

Assist[®] Service

Providing immediate post-
shock patient support



Kestra CareStation[®] Platform

Delivering actionable, alert-
based clinical insights

Heart Alert[™] Services

Proactive review of alerts with clinician & patient notification of
clinically actionable events



ACE-PAS Demonstrates Real-World Effectiveness

WCD monitoring and detection capability reveals broadening clinical utility

ACE-PAS Confirms Performance at Scale (>21,000 Patients)

Key Findings



Primary Endpoints

- 100% all-shock conversion
- Exceptionally low inappropriate shock rate (0.0065 per patient-month)




Secondary Endpoints

- 0.6% incidence per month (7.5 per 100 patient-years) of life-threatening VT/VF underscores need for early protection
- Detected actionable arrhythmias

Based on ACE-PAS study

Exceptionally Low False Alarms in Real-World Use

% of Patients Experiencing False Alarm



Real-World Insights to Inform Platform Evolution

Expanded Clinical Use

- High prevalence of complex patients with multiple cardiac comorbidities
- Frequent detection of clinically actionable non-VT/VF arrhythmias
- Extended monitoring windows aligned with GDMT optimization and recovery

Common Co-Morbidities



AF



Hypertension



Coronary Artery Disease

A Flexible Foundation for Long-Term Expansion



The ASSURE Platform is built to support new sensors, new data streams & future clinical applications

Powerful Today

- ✓ ASSURE® WCD with differentiated patient experience
- ✓ Integrated digital platform
- ✓ Continuous rhythm data supporting real-world clinical decisions
- ✓ Commercial infrastructure operating at scale

Designed for Durable Expansion

- ✓ Robust IP protection across algorithms, UX, hardware, sensors
- ✓ Regulatory, reimbursement & care delivery infrastructure
- ✓ Supports multi-sensor / future applications

Platform Extensibility in Action

Future Biobeat™ Sensor Integration

- ✓ First and only FDA-cleared wireless, cuffless 24-hour blood pressure monitoring sensor—enabling continuous, non-invasive vital sign capture with automated clinical reporting
- ✓ New modality to be added using core infrastructure
- ✓ Validates platform design for clinical expansion




FIRST & ONLY

Built on a Strong IP Foundation: 379 issued and pending patents worldwide

Commercial Team Expanding Rapidly

Achieving broad insurance coverage has led to an accelerated sales team buildout

Expanding Payor Coverage Supported by Established Medicare Coding



Commercial Scale Aligned to WCD Demand



1. As of January 2026. Based on internal and third-party estimates


*Based on January 2026 DMEPOS Fee Schedule

Targeting High Prescribing Hospitals & Clinics




WCD prescriber concentration provides roadmap for sales territory prioritization

Annual U.S. Prescription Volume by Hospital¹



Increasing Market Coverage

Number of Sales Territory Managers



1. Based on internal and third-party estimates as of November 2024.

Business Model & Key Drivers

Significant progress since commercial launch on each of the key drivers for growth and scale




Rental Model Provides Attractive Unit Economics



Eight quarters in a row of Gross Margin expansion

Gross Margin Expansion





Key Drivers of Margin Expansion

- ✓ Increased reimbursement realization due to improved market access via payor contracts and resulting shift in patient mix towards in-network patients
- ✓ Investments in revenue cycle management to drive increased cash collections from payors
- ✓ As depreciation of WCDs is distributed across fittings and WCD fleet is re-used, cost of goods per patient decreases as the number of fittings increases
- ✓ Supply chain efficiencies from higher volume purchases of components and manufacturing process improvements

Strong Commercial Progress

Delivering top-tier medtech growth rates



Fiscal Year (FY) ends April 30.

* Represents FY26 revenue guidance.

Foundation Set for Durable Long-Term Growth



Large, Expanding Market

- ✓ Existing \$1B+ WCD market growth has accelerated to low-mid teens



Compelling Clinical Data

- ✓ ACE-PAS has the potential to influence guidelines and unlock \$9B unpenetrated TAM



Attractive Unit Economics

- ✓ 70%+ gross margins at scale with significant operating leverage

Commercial Scale

- ✓ Rapid sales coverage expansion: 48 → 100 territories in 18 months



Robust R&D Innovation Engine

- ✓ BioBeat integration validates platform extensibility, enabling first-to-market combined therapy & extended VSM solution



N A S D A Q
KMTS

Thank You

